News

With few real-life studies that have specifically focused on how atopic dermatitis (AD) affects patients living with the ...
President Trump signed an executive order aiming to cut prescription drug costs by bringing the price the U.S. pays in line with comparable developed nations.
Dupilumab use in asthma linked to higher lymphoma risk, especially T/NK cell types, though overall mortality was lower, new study finds.
Discover a study where results suggest a statistically significant association between dupilumab and psoriasis, although the clinical impact may be limited.
People in states that have banned abortion were more than twice as likely to receive them later in pregnancy, according to a new study by researchers at UC San Francisco. The delays are primarily due ...
The Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
Its primary purpose is treatment, ensuring a robust evaluation of Dupilumab’s efficacy and safety. The study began on January 3, 2024, with primary completion expected in 2025.
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous pemphigoid, a rare blistering skin disease primarily affecting elderly patients.
Dupilumab treatment in patients with CRSwNP led to a healthier nasal microbiota by increasing beneficial bacteria like Lawsonella and Corynebacterium. The gut microbiota showed no effect, indicating ...
BP is a chronic, debilitating and relapsing rare skin disease affecting approximately 27,000 adults in the U.S. whose disease is uncontrolled by systemic corticosteroids ...